List of Excipients in Branded Drug PRED FORTE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	PRED FORTE	prednisolone acetate	11980-180	BENZALKONIUM CHLORIDE
Allergan Inc	PRED FORTE	prednisolone acetate	11980-180	BORIC ACID
Allergan Inc	PRED FORTE	prednisolone acetate	11980-180	EDETATE DISODIUM
Allergan Inc	PRED FORTE	prednisolone acetate	11980-180	HYPROMELLOSE

PRED FORTE Excipient Strategy and Commercial Opportunities

Last updated: August 31, 2026

PRED FORTE is a prednisolone acetate 1% ophthalmic suspension used for corticosteroid-responsive ocular inflammation. Its commercial position is driven by formulation performance, product usability, packaging, and regulatory execution rather than active-ingredient exclusivity. The reference formulation uses boric acid, edetate disodium, polysorbate 80, sodium citrate, sodium chloride, and water for injection. The principal opportunities are preservative-free delivery, improved resuspension, multidose packaging, lower ocular irritation, and differentiated manufacturing controls.

What is PRED FORTE and how is it regulated?

PRED FORTE contains micronized prednisolone acetate at a concentration of 1% for topical ophthalmic administration. The product is a sterile suspension, not a solution, because prednisolone acetate has limited aqueous solubility. The suspension format creates the central technical and commercial challenge: the product must deliver a consistent dose after shaking while maintaining physical stability during storage and use.

Attribute	PRED FORTE profile
Active ingredient	Prednisolone acetate
Strength	1% ophthalmic suspension
Dosage form	Sterile topical ocular suspension
Reference sponsor	AbbVie, through the former Allergan portfolio
FDA application	NDA 018780
Regulatory pathway	Full NDA reference product; generic competitors generally use ANDA pathway
Therapeutic class	Ophthalmic corticosteroid
Primary uses	Postoperative and other steroid-responsive ocular inflammation
Biosimilar pathway	Not applicable
Main competitive threat	Generic prednisolone acetate ophthalmic suspensions

The FDA label identifies the inactive ingredients as boric acid, edetate disodium, polysorbate 80, sodium citrate, sodium chloride, and water for injection. The formulation may be pH-adjusted with hydrochloric acid or sodium hydroxide. The product must be shaken before use because the active ingredient remains dispersed rather than dissolved (U.S. Food and Drug Administration [FDA], 2023a).

What excipients are used in PRED FORTE?

The excipient system performs several separate functions: wetting the hydrophobic steroid particles, controlling pH, maintaining tonicity, limiting metal-catalyzed degradation, and supporting physical stability.

Excipient	Likely formulation function	Commercial and IP significance
Boric acid	Buffering and tonicity contribution	Common ophthalmic excipient; limited standalone patent value
Sodium citrate	Buffer system and pH control	Helps maintain ocular-compatible pH; may support stability claims in combination
Sodium chloride	Tonicity adjustment	Important for comfort and osmolality control
Polysorbate 80	Wetting and dispersing agent	Reduces particle aggregation and supports dose uniformity
Edetate disodium	Chelating agent	Binds trace metals that may promote degradation or instability
Water for injection	Sterile aqueous vehicle	Required for ophthalmic manufacturing and microbial control

PRED FORTE’s formulation is comparatively restrained. It does not depend on a high-viscosity polymer, a sophisticated drug-delivery carrier, or a conventional antimicrobial preservative listed in the FDA inactive-ingredient description. That creates both a tolerability advantage and a manufacturing burden.

Why does prednisolone acetate require a suspension?

Prednisolone acetate is poorly water soluble. A suspension allows the drug to remain at a therapeutically useful concentration without relying on cosolvents or surfactant levels that could increase ocular irritation.

The main quality attributes are:

• Particle-size distribution
• Crystal form and polymorphic stability
• Sedimentation rate
• Ease and speed of redispersion
• Dose uniformity through the bottle
• Viscosity
• pH and osmolality
• Sterility
• Container-closure compatibility
• Stability after opening

A technically weak suspension can produce an initial underdose or overdose, particularly if the bottle is not adequately shaken. The commercial value of a reformulation therefore lies in reproducible dose delivery, not simply in adding another excipient.

What formulation patents could protect a PRED FORTE competitor?

The legacy PRED FORTE excipient combination is unlikely to support broad, durable composition claims by itself. The ingredients are established ophthalmic excipients, and prednisolone acetate suspension technology has substantial prior art. New patent value would come from defined performance parameters or a technically distinct delivery system.

Particle engineering and redispersion

Potential claims could cover:

• A narrow prednisolone acetate particle-size distribution
• Controlled D90 or D50 limits
• Crystal morphology or polymorphic form
• A defined zeta-potential range
• A specific sedimentation volume
• Redispersion within a specified number of inversions
• Dose uniformity after defined shaking conditions

These claims are commercially relevant because a generic or branded product can be differentiated by ease of use and consistent delivered dose. They are also vulnerable if the claimed parameters are inherent in routine micronization or standard suspension processing.

Surfactant and buffer combinations

Polysorbate 80 is a logical wetting agent for prednisolone acetate. A patent strategy could focus on a defined ratio of drug, surfactant, buffer, chelator, and tonicity agent that produces a measurable improvement in particle wetting, suspension stability, or ocular comfort.

The claim must be tied to evidence such as:

• Lower aggregation after accelerated storage
• Improved dose uniformity
• Lower shaking energy
• Reduced particle growth
• Lower preservative or surfactant exposure
• Better stability after repeated bottle opening

A generic claim that merely lists boric acid, sodium chloride, polysorbate 80, and EDTA would face substantial obviousness risk.

Preservative-free multidose systems

A preservative-free multidose bottle is the strongest commercial white-space opportunity. The technical barrier is maintaining sterility after repeated use without benzalkonium chloride or another conventional preservative.

Patentable elements may include:

• One-way valve architecture
• Airless dispensing
• Filtered or sealed venting
• Tip protection
• Internal antimicrobial surfaces
• Defined extractables and leachables controls
• A bottle system that prevents backflow into the drug reservoir

The patent estate would likely center on the container-closure system and dispensing method rather than on prednisolone acetate chemistry.

Viscosity and residence-time technologies

A modest increase in viscosity can improve ocular residence time and reduce dosing frequency. Possible excipients include cellulose derivatives, carbomers, povidone, or other ophthalmic polymers. The risks are increased blurring, slower redispersion, altered drop size, and greater manufacturing complexity.

A viable patent would need to link viscosity to a specific benefit, such as improved ocular exposure without compromising suspension uniformity or drop administration.

When did PRED FORTE lose exclusivity?

PRED FORTE is a mature small-molecule ophthalmic product. Its original compound and product protections expired long before the current generic market developed. The FDA Orange Book identifies NDA 018780 as the reference application, but PRED FORTE does not present the type of active patent barrier associated with recently approved branded products (FDA, 2024).

Exclusivity issue	PRED FORTE position
New chemical entity exclusivity	Expired
Original formulation exclusivity	Expired
Pediatric exclusivity	No current commercial relevance
Orphan exclusivity	Not applicable
Biosimilar exclusivity	Not applicable
Current protection focus	Brand, manufacturing quality, device, and potential reformulation patents

The absence of meaningful active-ingredient exclusivity means that a competitor can pursue an ANDA for prednisolone acetate ophthalmic suspension if it satisfies FDA requirements for pharmaceutical equivalence, bioequivalence, quality, sterility, and labeling.

What is the Orange Book status of PRED FORTE?

The key Orange Book issue is the absence of a meaningful unexpired patent barrier associated with the original product. A generic applicant therefore has limited need to make a Paragraph IV certification against a blocking PRED FORTE patent. The principal certification issue is generally whether listed patents exist and remain relevant, not whether a competitor can overcome a current composition-of-matter patent.

What does this mean for Paragraph IV challenges?

Paragraph IV litigation is less central for PRED FORTE than for a drug with active Orange Book patents. Generic companies can compete through the ANDA process without depending on a court invalidation of a core patent, assuming the Orange Book entry does not contain a relevant unexpired formulation or method-of-use patent.

A brand owner seeking to delay entry would need a new, properly listed patent covering a differentiated formulation, delivery system, or approved method of use. Such patents would not automatically block all prednisolone acetate suspensions. Their scope would depend on the specific claims and the generic product’s formulation and labeling.

What commercial opportunities exist for PRED FORTE excipients?

Preservative-free single-dose units

Unit-dose ampoules can target:

• Postoperative patients
• Chronic users with ocular-surface disease
• Patients sensitive to preservatives
• Hospitals and ambulatory surgery centers
• Ophthalmologists seeking reduced preservative exposure

The disadvantages are higher packaging cost, more waste, greater shipping volume, and lower convenience for patients requiring treatment over multiple days.

Preservative-free multidose bottles

This option has stronger commercial potential than a simple unit-dose copy because it combines patient convenience with a meaningful product distinction. The primary development risk is maintaining sterility throughout in-use testing under actual handling conditions.

A successful product could compete on:

• Preservative-free labeling
• Longer in-use period
• Improved drop consistency
• Lower contamination risk
• Easier administration
• Compatibility with postoperative prescribing protocols

Improved-shake formulation

A suspension that redisperses rapidly could address a direct usability problem. The product could use optimized particle engineering, surfactant concentration, viscosity, or flocculation control. Labeling claims should rely on validated in-use performance rather than general statements about "better suspension stability."

Lower-irritation formulation

Boric acid, citrate, surfactant concentration, osmolality, and pH can affect comfort. A reformulation could target patients who experience burning or blurred vision after administration. Any commercial claim would require clinical or human-factors evidence because excipient changes can alter tolerability without improving efficacy.

Hospital and surgery-center packaging

Small-volume, unit-dose or controlled-dispensing formats can support institutional purchasing. Relevant features include tamper evidence, barcode compatibility, simplified storage, and packaging that minimizes contamination during postoperative care.

How strong is the patent estate for a PRED FORTE reformulation?

The patent strength is likely to be moderate for a narrowly defined formulation and weak for a conventional excipient substitution.

Strategy	Patent strength	Regulatory complexity	Commercial value
Same formulation with different bottle	Low	Low to moderate	Low
New particle-size distribution	Moderate	Moderate	Moderate
Improved redispersion suspension	Moderate to strong if data-supported	Moderate	High
Preservative-free unit dose	Moderate	Moderate	Moderate
Preservative-free multidose device	Stronger device opportunity	High	High
Viscosity-enhanced suspension	Moderate	Moderate to high	Moderate
New dosing regimen	Variable	High	Potentially high
New ocular indication	Potentially strong	Very high	High
Manufacturing process controls	Moderate trade-secret value	Moderate	Moderate

Process protection may be more valuable than composition protection. Controlled micronization, sterile milling, order of addition, mixing energy, hold times, and aseptic filling parameters can materially affect product performance. These methods can be protected through trade secrets even when patent claims would be vulnerable.

What FDA regulatory pathway applies to a generic PRED FORTE product?

A conventional generic would generally pursue an ANDA referencing prednisolone acetate ophthalmic suspension 1%. The applicant must demonstrate pharmaceutical equivalence and bioequivalence and satisfy requirements for sterility, impurities, stability, labeling, and manufacturing controls.

A materially different product may need a more complex regulatory strategy. Examples include:

• A new preservative-free multidose system
• A novel delivery device
• A materially different viscosity profile
• A new indication
• A different dosing frequency
• A formulation with a new excipient not previously used in the relevant ophthalmic context

FDA product-specific guidance and ophthalmic suspension expectations make physical characterization important. Key evidence can include particle-size distribution, rheology, redispersibility, delivered dose uniformity, droplet size, and comparative performance testing (FDA, 2023b).

Which companies are challenging PRED FORTE commercially?

Competition comes from generic manufacturers of prednisolone acetate ophthalmic suspension rather than biosimilar developers. The market includes established generic ophthalmic suppliers and branded ophthalmic companies with broader postoperative portfolios.

The competitive variables are:

• Wholesale acquisition price
• Contracting with ophthalmologists and surgery centers
• Supply reliability
• Bottle design
• Preservative profile
• Reimbursement status
• Shortage performance
• Product availability in multiple bottle sizes

A low-cost generic can capture volume, but a differentiated product can preserve pricing through preservative-free delivery, device convenience, or improved suspension performance.

What litigation and settlement risks affect PRED FORTE?

The litigation profile is structurally lower than for a recently approved drug because the original product lacks a current composition-of-matter barrier. The more important risks for a reformulated product are:

1. A patent owner asserts particle-size or suspension-performance claims.
2. A device patent covers the multidose container.
3. A method-of-use patent is listed for a specific postoperative or inflammatory indication.
4. An ANDA applicant receives a regulatory stay after a patent lawsuit.
5. A formulation patent creates a narrow launch constraint rather than a market-wide block.

Settlement agreements are most relevant if a new branded reformulation creates Orange Book-listed patents. A settlement could permit an agreed generic launch date, license a device, or restrict use of a patented indication. It would not necessarily prevent an unclaimed prednisolone acetate product from entering the market.

How does PRED FORTE compare with competing ophthalmic corticosteroids?

Product or class	Main differentiation	Excipient opportunity
Prednisolone acetate 1% suspension	Established potency and clinical familiarity	Redispersion, preservative-free delivery, device
Prednisolone sodium phosphate solution	Water-soluble solution; potentially easier administration	Comfort, stability, dose delivery
Loteprednol etabonate suspension or gel	Steroid designed for potentially improved safety profile	Gel systems, particle engineering, longer residence
Dexamethasone suspension or solution	Alternative corticosteroid potency and formulations	Solution stability and multidose preservation
Fluorometholone products	Lower-potency steroid positioning	Comfort and chronic-use formulation
Difluprednate emulsion	Potent emulsion-based corticosteroid	Emulsion stability and reduced dosing frequency

PRED FORTE’s commercial advantage is physician familiarity and established use. Its weakness is the need to shake the bottle and the difficulty of differentiating a conventional generic on clinical grounds.

What geographic opportunities exist?

The United States offers a large established generic market but limited exclusivity protection. Europe, Canada, Japan, and emerging markets may offer opportunities for:

• Preservative-free presentations
• Unit-dose hospital products
• Local manufacturing
• Supply contracts
• Products adapted to regional packaging requirements
• Licensing of a proprietary multidose device

Global excipient acceptability must be assessed by jurisdiction. A formulation accepted in the United States may require different regulatory justification elsewhere, particularly for preservative-free multidose systems, novel polymers, or device-integrated packaging.

Key Takeaways

• PRED FORTE is a prednisolone acetate 1% ophthalmic suspension with an established excipient system.
• The formulation uses boric acid, sodium citrate, sodium chloride, polysorbate 80, edetate disodium, and water for injection.
• The original product has no meaningful current active-ingredient exclusivity barrier.
• Conventional generic competition is primarily an ANDA and manufacturing-execution issue.
• The strongest commercial opportunities are preservative-free multidose delivery, improved redispersion, lower-irritation formulations, and unit-dose institutional packaging.
• Broad excipient patents are weak prospects; narrow performance claims and device patents are more defensible.
• There is no biosimilar pathway because PRED FORTE is a small-molecule ophthalmic product.
• Manufacturing know-how, suspension control, sterile filling, and container-closure performance may provide greater practical protection than a broad composition patent.

FAQs

Can a preservative-free PRED FORTE generic be approved through an ANDA?

Yes, if the product meets applicable ANDA requirements and the inactive-ingredient differences do not create a safety or effectiveness concern. A novel multidose container may require extensive device and in-use sterility data.

Which PRED FORTE excipient is most important for suspension performance?

Polysorbate 80 is central to wetting and dispersion, but performance depends on the combined system of particle size, surfactant level, buffer, ionic strength, mixing process, and viscosity.

Does PRED FORTE require a Paragraph IV certification?

Only if a relevant unexpired patent is listed for the reference product. Because the original product is mature and lacks a meaningful active-ingredient patent barrier, Paragraph IV litigation is not the primary entry issue.

Is a prednisolone acetate ophthalmic suspension patentable today?

A broad claim to prednisolone acetate with conventional ophthalmic excipients is unlikely to be strong. Patentability improves when the claims cover demonstrated improvements in particle engineering, redispersion, dose uniformity, preservative-free multidose delivery, or device architecture.

What is the highest-value commercial reformulation?

A preservative-free multidose suspension with rapid redispersion and validated in-use sterility offers the strongest combination of patient differentiation, institutional value, and potential device or formulation protection.

References

1. U.S. Food and Drug Administration. (2023a). PRED FORTE (prednisolone acetate ophthalmic suspension, USP) 1% prescribing information. AbbVie Inc.

2. U.S. Food and Drug Administration. (2023b). Product-specific guidance on prednisolone acetate ophthalmic suspension. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

4. United States Pharmacopeia. (2024). General chapter <771>: Ophthalmic products. United States Pharmacopeial Convention.

5. U.S. Food and Drug Administration. (2019). Container closure systems for packaging human drugs and biologics: Guidance for industry. Center for Drug Evaluation and Research.